Injectable viles.

Hikma intros succinylcholine chloride injection

Succinylcholine chloride injection had a market value of roughly $43 million in the 12 months ended May 2021, according to IQVIA.
Levy

Hikma is offering succinylcholine chloride injection, 20mg/ml.

The product is used in the treatment of COVID-19 patients. It is indicated, in addition to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

“We are very pleased to launch succinylcholine chloride injection in the U.S., a neuromuscular blocking agent and an important drug used in the treatment of COVID-19,” said Riad Mishlawi, president of Injectables. “Hikma is committed to making affordable medicines accessible to those in need and is proud to be supplying the US market with a wide portfolio of injectable medicines used to treat COVID-19 patients in intensive care.”

Succinylcholine chloride injection had a market value of roughly $43 million in the 12 months ending May 2021, according to IQVIA.

 

X
This ad will auto-close in 10 seconds